NasdaqGS:REPLBiotechs
Replimune Group (REPL) Wins FDA Approval, Is The Valuation Still Too Rich?
Replimune Group (REPL) stock is back in focus after Robbins LLP announced a securities class action tied to the company’s RP1 melanoma program and the U.S. Food and Drug Administration’s April 2026 Complete Response Letter.
See our latest analysis for Replimune Group.
Investors have been weighing the legal overhang from the RP1 class action against fresh momentum after the FDA granted accelerated approval for TUDRIQEV, with Replimune Group’s share price at $12.06 reflecting a 90 day share...